New oral antithrombotics: A need for laboratory monitoring. For

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 4, 2010, Pages 621-626

  Mismetti, P ^a,b   Laporte, S ^b  

^a University Jean Monnet of Saint Etienne EA3065   (France)

^b Saint Etienne Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CALIBRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DETERMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; HEART ATRIUM FIBRILLATION; HUMAN; INDIVIDUALITY; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; VITAMIN K; WARFARIN;

EID: 77952679761     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03764.x     Document Type: Article

References (38)

1. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-92.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-51.
3. Taberner DA, Poller L, Thomson JM, Darby KV. Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR). J Clin Pathol 1989, 42:92-6.
4. Palareti G, Coccheri S, Poggi M, Bonetti M, Cervi V, Mazzuca A, Savoia M, Veri L, Fiori F, Gaspari G. Oral anticoagulant therapy control: evidence that INR expression improves the inter-laboratory comparability of results--the Bologna oral anticoagulant control exercise. Thromb Haemost 1987, 58:905-10.
5. Woodhams BJ, Klein N, Harz D, Rose M, Ruiz JA. A study of the variability seen in the international normalized ratio obtained using different sensitivity thromboplastin reagents on different instrument types. Blood Coagul Fibrinolysis 1999, 10:423-7.
6. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993, 329:696-702.
7. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540-6.
8. Palareti G, Hirsh J, Legnani C, Manotti C, D'Angelo A, Pengo V, Moia M, Guazzaloca G, Musolesi S, Coccheri S. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000, 160:470-8.
9. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349:631-9.
10. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-8.
11. Smythe MA, Mattson JC, Koerber JM. The heparin anti-Xa therapeutic range: are we there yet? Chest 2002, 121:303-4.
12. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997, 157:2562-8.
13. Anand SS, Bates S, Ginsberg JS, Levine M, Buller H, Prins M, Haley S, Kearon C, Hirsh J, Gent M. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999, 159:2029-32.
14. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-702.
15. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296:935-42.
16. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994, 71:698-702.
17. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793-800.
18. Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderink GJ, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003, 56:407-14.
19. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005, 59:281-90.
20. Hulot JS, Montalescot G, Lechat P, Collet JP, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005, 77:542-52.
21. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-84.
22. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001, 80:81-2.
23. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004, 110:392-8.
24. Mahé I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K, Heilmann JJ, Mottier D, Bergmann JF. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007, 97:581-6.
25. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-315.
26. Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007, 147:304-10.
27. Monreal M, Falgá C, Valle R, Barba R, Bosco J, Beato JL, Maestre A. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006, 119:1073-9.
28. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008, 47:285-95.
29. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-61.
30. Mismetti P, Laporte S. Dabigatran: clinical pharmacology. Ann Fr Anesth Reanim 2009, 9(Suppl):S8-14.
31. Mismetti P, Laporte S. Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim 2008, 27(Suppl 3):S16-21.
32. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo M-L, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005, 3:103-11. for the BISTRO II Study Group
33. Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006, 62:527-37.
34. Giugliano R, Rohatagi S, Kastrissios H. The relationship between oral factor Xa inhibitor DU-176B pharmacokinetics and the probability of bleeding events (BE) in patients with atrial fibrillation (AF). J Thromb Haemost 2009, OC-WE-003. suppl
35. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24:1-9.
36. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-56.
37. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-85.
38. Dahl OE. Dabigatran etexilate for the prophylaxis of venous thrombo-embolism after hip or knee replacement: rationale for dose regimen. Clin Appl Thromb Hemost 2009, http://dx.doi.org/10.1177/1076029609344588, DOI: